The value of Trade Secrets theft in the United States is estimated to be between $180 billion and $450 billion per year. Pharmaceutical corporations, which are among the world’s most research-intensive organisations, are among the targets of this theft. Pharmaceutical research necessitates a lot of time and effort, and it frequently results in private data that is crucial to pharmaceutical development. Pharmaceutical businesses adopt numerous methods to protect their intellectual information because such data may be particularly appealing to threat actors.
Those experiments, according to Venn, showed that the antibody successfully suppressed a cell receptor linked to cancer growth. Venn subsequently went into an exclusive negotiation agreement with the University in March 2020 to licence VTX-002, an antibody generated from VTX-001 that was demonstrated to be even more effective than VTX-001 in early testing, based on the promising results of VTX-001. The University could not solicit or entertain any bid for VTX-002 from a third party until December 2020, according to the exclusive negotiation agreement.
Be First to Comment